Title |
Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study
|
---|---|
Published in |
Critical Care, October 2014
|
DOI | 10.1186/s13054-014-0534-9 |
Pubmed ID | |
Authors |
Lakhmir S Chawla, Laurence Busse, Ermira Brasha-Mitchell, Danielle Davison, Jacqueline Honiq, Ziyad Alotaibi, Michael G Seneff |
Abstract |
IntroductionPatients with distributive shock who require high dose vasopressors have a high mortality. Angiotensin II (ATII) may prove useful in patients who remain hypotensive despite catecholamine and vasopressin therapy. The appropriate dose of parenteral angiotensin II for shock is unknown.MethodsIn total, 20 patients with distributive shock and a cardiovascular Sequential Organ Failure Assessment score of 4 were randomized to either ATII infusion (N¿=¿10) or placebo (N¿=¿10) plus standard of care. ATII was started at a dose of 20 ng/kg/min, and titrated for a goal of maintaining a mean arterial pressure (MAP) of 65 mmHg. The infusion (either ATII or placebo) was continued for 6 hours then titrated off. The primary endpoint was the effect of ATII on the standing dose of norepinephrine required to maintain a MAP of 65 mmHg.ResultsATII resulted in marked reduction in norepinephrine dosing in all patients. The mean hour 1 norepinephrine dose for the placebo cohort was 27.6¿±¿29.3 mcg/min versus 7.4¿±¿12.4 mcg/min for the ATII cohort (P¿=¿0.06). The most common adverse event attributable to ATII was hypertension, which occurred in 20% of patients receiving ATII. 30-day mortality for the ATII cohort and the placebo cohort was similar (50% versus 60%, P¿=¿1.00).ConclusionAngiotensin II is an effective rescue vasopressor agent in patients with distributive shock requiring multiple vasopressors. The initial dose range of ATII that appears to be appropriate for patients with distributive shock is 2 to 10 ng/kg/min.Trial registrationClinicaltrials.gov NCT01393782. Registered 12 July 2011. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 20% |
United States | 1 | 10% |
Mexico | 1 | 10% |
Egypt | 1 | 10% |
Canada | 1 | 10% |
Italy | 1 | 10% |
Unknown | 3 | 30% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 7 | 70% |
Scientists | 2 | 20% |
Science communicators (journalists, bloggers, editors) | 1 | 10% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 1 | <1% |
Unknown | 153 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 20 | 13% |
Student > Doctoral Student | 18 | 12% |
Other | 14 | 9% |
Student > Master | 14 | 9% |
Student > Bachelor | 11 | 7% |
Other | 32 | 21% |
Unknown | 45 | 29% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 73 | 47% |
Nursing and Health Professions | 5 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 3% |
Psychology | 4 | 3% |
Computer Science | 3 | 2% |
Other | 19 | 12% |
Unknown | 45 | 29% |